Progressive Supranuclear Palsy (PSP) following COVID-19 Gene Therapy Products (GTPs).
Parkinson’s Disease on Steroids
Central Nervous System: Anatomic-Function Correlation
The brain is the most complicated organ by far. Pathological processes affect different areas of the nervous system which produce diverse and profound effects, some of which are outlined in the neurological diseases presented below.
We know from Dr. Arne Burkhardt’s foundational work in histopathology of CoVax Disease (illnesses following GTPs) that the central nervous system, brain, and spinal cord are potential targets of spike protein translated from modRNA (modified RNA) in the LNP/mRNAs.
Dr. Burkhardt identified the following pathological processes in the brain tissue following “vaccination.”
a) Encephalitis is inflammation of the brain from indeterminate cause compared to reaction b) inflammation from attack of killer T cells on tissues with non-self spike proteins.
c) Microthrombi are small blood clots, d) aneurysms are splits and bulges in the muscle layer of the artery.
e) Subarachnoid hemorrhage is bleeding below the inner two and three layers of tissues covering the brain.
f) The dura matter is the outer of the three layers of tissues covering the brain and lies next to the bone on the inner aspect of the skull.
g) Finally, amyloid deposits are collections of abnormal protein fibers that interfere with normal nerve function.
Each of these processes can potentially affect multiple areas. This article will begin a series of articles on the diverse manifestations of central nervous system (CNS) disease following COVID-19 gene therapy drugs.
Progressive Supranuclear Palsy (PSP) (Steele-Richardson-Olszewski Syndrome), 16 cases in the VAERS database
From the Mayo Clinic,
The actual cause of the progressive supranuclear palsy (PSP)-related deterioration is not well known. In post-LNP/mRNA treatment, special autopsies are required to understand which of the mechanisms identified by Dr. Burkhardt’s group and listed above are part of the disease process in PSP.
Prevalence
Estimates of the true prevalence of diseases found in VAERS have been anywhere from 10 to 100 times the numbers reported. These multiples may be underestimates given government manipulation of the data. (For more about data integrity in VAERS see Albert Benavides’ Substack.)
VAERS reports cannot be relied upon to establish causation. Temporal proximity does not establish causation. The red flag signal here indicative of the need for a special investigation is the appearance of 16 cases of PSP for the first time beginning in 2021, the year of the largest mass vaccination event of the COVID-19 era.
Neuroanatomy of PSP
PSP involves deep regions of the brain and cerebellum (balance). Often cranial nerves are involved. There are 12 cranial nerves on each side of the head. These nerves will be more familiar from their text names rather than their number I-XII.
https://www.thoughtco.com/cranial-nerves-function-373179
Key diagnostic clues for this condition are a combination of what are called cerebellar signs (below) and cranial nerve involvement.
https://www.pinterest.com/pin/163325923960674313/
Symptoms and Physical Findings
The following is from the National Institutes of Health (NIH):
“PSP affects a person’s movements, and can lead to loss of balance, difficulty walking or swallowing, slurred speech, problems with eye movements. PSP can also affect a person’s mood, behavior, and thinking. The most frequent first symptom of PSP is a loss of balance while walking which can lead to abrupt and unexplained falls. People with PSP may also have stiffness and slow movement.
As the disease progresses, most people develop eye problems. Eye and vision symptoms may include:
Slow eye movements
Trouble looking up or down
Trouble controlling eyelids, involuntary closing of the eyes, decreased blinking, or difficulty opening the eyes
Tendency to move the head rather than just the eyes to look in different directions
People with PSP and their loved ones may notice changes in mood or behavior. These may include:
Depression
Lack of motivation
Changes in judgment, insight, and problem solving
Difficulty finding words
Forgetfulness
Loss of interest in activities the person used to enjoy
Increased irritability
Sudden laughing, crying, or angry outbursts for no apparent reason
Personality changes
Slowed, slurred, or monotone speech
Difficulty swallowing
Mask-like facial expressions
Sleep problems”
https://www.ninds.nih.gov/health-information/disorders/progressive-supranuclear-palsy-psp
The presentation of this disease is presented in the following two videos.
Epidemiology of Non COVID-19 “Vaccine” Cases
The prevalence of PSP has been estimated as 5.8-6.5% per 100,000, and the incidence is 0.3 to 1.1 per 100,000 according to Agarwal and Gilbert. Mean age at onset was 65, and onset under 40 would be unique. (https://www.ncbi.nlm.nih.gov/books/NBK526098/)/
Diagnostic Studies
There are no diagnostic tests that can be called pathognomonic, specific to this disease, but there are common findings as seen in the MRI images below.
“Sagittal midline image demonstrates atrophy of the midbrain which is concave at its cranial margin (hummingbird sign). This concavity is also evident laterally on axial images (morning glory sign). These changes are disproportionate to the pontine volume with a pontine: midbrain ratio of 0.13 (normal ~0.24). Superior cerebellar peduncles are thinned.”
https://radiopaedia.org/cases/48610/studies/53609?lang=us
This means there is atrophy in the middle of the brain and cerebellum.
PSP in VAERS after COVID-19 Gene Therapy
There were no cases of PSP in VAERS prior to introduction of COVID-19 gene therapy products. There were 14 in 2021 and two in 2022. Nine of 16 cases occurred in males, and the average age was 73.5 years.
Case courtesy of Frank Gaillard. From the case https://radiopaedia.org/cases/34485?lang=us.
75% of PSP cases in VAERS had more than a single dose of COVID LNP/mRNA Gene Therapy. Four patients had a single dose, eight had two doses, and four had three doses.
A Case History from VAERS
“PROGRESSIVE SUPRANUCLEAR PALSY COVID19 (COVID19 (MODERNA)) Male 80+ years. VAERS # 1696794-1.
PT had 3 strokes on 2/23/2021, Tuesday, between 8:00-9:00 a.m. This was less than 48 hours after his 2nd Moderna shot on Sunday, 2/21/2021, at 10:00 a.m.
On Monday, the next day after his 2nd Moderna shot, he felt unwell, was irritable and took a long nap.
On Tuesday, the second morning after his 2nd Moderna shot, his arms and legs started involuntarily shaking and twitching. He complained of having a very bad headache, threw-up and could no longer stand. He used his arms to lower his body. He happened to be in the bathroom? He lowered his body into the bathtub, as he lost control of his legs. I discovered him lying in the bathtub, unresponsive, with his eyes tightly closed. I tried to move him from the bathtub initially, but his legs would not work and were unresponsive. He held the weight of his body up by a bar in the bathtub, as his legs were not working. I called 911.
He was taken in an ambulance to the emergency room. The emergency room staff did not know what was wrong with him and initially tried to discharged (sic) him, but he was unable to walk out of the hospital.
From the emergency room, he was then admitted to the hospital. He stayed in the hospital for 5 days. After receiving a head MRI, he was diagnosed with having 3 strokes. He still was having great difficulty walking and was having balance problems. His legs appeared unresponsive, rigid and stiff. Vision was affected as well. He could not see on his right side; he was unable to see the food tray or silverware when he was eating. His cognition/brain/mental capacity was obviously affected. He did not know his correct age, and could not remember short-term and long-term events. He lost some use of language. He had a lot of trouble using the telephone.
After 5 days in the hospital, pt was admitted to a physical rehabilitation center for 16 days. He attended physical therapy, occupational therapy and speech therapy daily. By the time he discharged, he was walking with a walker. He did NOT use a walker pre-stroke.
He also still had significant loss of language, memory and cognitive ability. He still could not see well on the right side, and would often walk into visible obstacles / walls on his right side as he could not see them.
After the rehabilitation center, pt returned home and had home healthcare services. He had Occupational therapy, physical therapy, speech therapy, 1:1 nurse, as well as a home health aide who helped him to shower. At home, he (sic) some Occupational Therapy and Physical Therapy sessions.
Due to his new vision and balance problems following the strokes, and being newly on a blood thinner after the adverse reaction, he was in danger of falling and needed the home health aide to assist with bathing ( so that he would NOT fall in the shower). Speech (cognitive) therapy lasted the longest out of all 3 home healthcare therapies.
Even at the close of speech therapy, he still presented significant deficits in both short-term and long-term memory, as well as in his cognitive ability. He can no longer budget his finances.
On June 29th, a neurological ophthalmologist diagnosed him with loss of peripheral vision on both right sides. He lost right peripheral vision in both eyes.
These 3 strokes, following the 2nd Moderna shot, greatly changed pt’s quality of life. Prior to the vaccine and strokes, he used to drive, take care of his grandchildren, manage his finances, shop for food, clean and cook daily, as well “”care-take”” for his wife who has her own physical injuries.
He was 100% independent and helped many members of his family regularly. He helped his family with day-to-day practical tasks, offered emotional support, career direction, and shared his wisdom regularly.
Today, almost 7 months later, he can no longer drive, manage his finances nor bank accounts. He regularly writes checks for money he does not have. His mental capacity is extremely diminished. He also gets lost easily. When he is dropped off at a doctor?s (sic} appointment in a hospital on his own, he easily gets lost and confused.
He is also more easily frustrated, confused and irritated. This causes great strain on his relationships with his wife and family, as he used to be the solid foundation of the family. He has still lost all right peripheral vision in both eyes. His vision has not returned. He also still struggles with both his short-term and long-term memory, and general cognitive / brain / mental function.
His quality of life is greatly affected and diminished. The quality of life of his family who depended upon him has been very negatively impacted as well."
The first dose may have set up the catastrophic response following the second dose, possibly through complement fixation or mass cytokine release in the midbrain.
Prognosis:
From the National Institutes of Health website:
“PSP has a typical duration of 5 to 7 years, sometimes longer, and a slow course is part of the diagnostic criteria. Although rare cases of PSP with more rapid progression have been described, they are typically over 2 to 3 years.” (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182982/)
There is no basis to know whether post COVID-19 GTP cases will follow these tendencies. CoVax PSP may have a unique prognosis.
Outcome, VAERS Cases:
Thirty-one percent had severe disease with one death, three life-threatening illnesses (one died), and two permanent disabilities.
To April 2022, Pfizer reported 6 Cases of Progressive Supranuclear Palsy plus thousands of other Palsy victims.